Panelists emphasize the complexity of choosing among available third-line therapies, noting that no single option fits all ...

Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...

Optimizing icIEF identifies mAbs more accurately, while staying within European Pharmacopoeia and ICH guidelines.

Tampa Bay's offense had a rare single-digit scoring output in Detroit on Monday night, and even in a short week heading into ...